VIVS · VivoSim Labs Inc. Common Stock
View on chartInsiders & Stakes
| Vaidehi Joshi Director | ▲ Buy | Grant | 58,821 Shares held | 8/7/2024 | View profile |
| Keith Murphy Executive Chairman | ▲ Buy | Grant | 26,053 Shares held | 1/27/2026 | View profile |
| Douglas Jay Cohen Director | ▲ Buy | Grant | 20,732 Shares held | 1/27/2026 | View profile |
| Adam K. Stern Director | ▲ Buy | Grant | 19,899 Shares held | 1/27/2026 | View profile |
| Alison Tjosvold Milhous Director | ▲ Buy | Grant | 19,899 Shares held | 1/27/2026 | View profile |
| David Gobel Director | ▲ Buy | Grant | 15,000 Shares held | 1/27/2026 | View profile |
| Lialin Tony Serge Chief Commercial Officer | ▲ Buy | Open Market | 10,000 Shares held | 8/31/2026 | View profile |
Transaction History
| Lialin Tony Serge | ▲ Buy | Open Market | 10,000 | $3K | 8/31/2026 |
| Keith Murphy | ▲ Buy | Grant | 15,000 | $0 | 1/27/2026 |
| Alison Tjosvold Milhous | ▲ Buy | Grant | 15,000 | $0 | 1/27/2026 |
| David Gobel | ▲ Buy | Grant | 15,000 | $0 | 1/27/2026 |
| Adam K. Stern | ▲ Buy | Grant | 15,000 | $0 | 1/27/2026 |
| Douglas Jay Cohen | ▲ Buy | Grant | 15,000 | $0 | 1/27/2026 |
| David Gobel | ▼ Sell | Open Market | 3,266 | $7K | 11/17/2025 |
| David Gobel | ▲ Buy | Grant | 19,607 | $0 | 8/7/2024 |
| Douglas Jay Cohen | ▲ Buy | Grant | 19,607 | $0 | 8/7/2024 |
| Alison Tjosvold Milhous | ▲ Buy | Grant | 19,607 | $0 | 8/7/2024 |
| Adam K. Stern | ▲ Buy | Grant | 19,607 | $0 | 8/7/2024 |
| Vaidehi Joshi | ▲ Buy | Grant | 19,607 | $0 | 8/7/2024 |
| Keith Murphy | ▲ Buy | Grant | 19,607 | $0 | 8/7/2024 |
| Adam K. Stern | ▲ Buy | Grant | 19,607 | $0 | 11/17/2023 |
| Alison Tjosvold Milhous | ▲ Buy | Grant | 19,607 | $0 | 11/17/2023 |
| Douglas Jay Cohen | ▲ Buy | Grant | 19,607 | $0 | 11/17/2023 |
| Keith Murphy | ▲ Buy | Grant | 19,607 | $0 | 11/17/2023 |
| David Gobel | ▲ Buy | Grant | 19,607 | $0 | 11/17/2023 |
| Vaidehi Joshi | ▲ Buy | Grant | 19,607 | $0 | 11/17/2023 |
| David Gobel | ▼ Sell | Open Market | 19,607 | $32K | 11/15/2023 |
| David Gobel | ▲ Buy | Grant | 19,607 | $0 | 11/10/2022 |
| Adam K. Stern | ▲ Buy | Grant | 19,607 | $0 | 11/10/2022 |
| Keith Murphy | ▲ Buy | Grant | 19,607 | $0 | 11/10/2022 |
| Alison Tjosvold Milhous | ▲ Buy | Grant | 19,607 | $0 | 11/10/2022 |
| Douglas Jay Cohen | ▲ Buy | Grant | 19,607 | $0 | 11/10/2022 |
| Vaidehi Joshi | ▲ Buy | Grant | 19,607 | $0 | 11/10/2022 |
| Douglas Jay Cohen | ▲ Buy | Open Market | 8,750 | $59K | 8/17/2021 |
| Douglas Jay Cohen | ▲ Buy | Open Market | 1,000 | $7K | 8/17/2021 |
| Douglas Jay Cohen | ▲ Buy | Open Market | 1,000 | $7K | 8/17/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing
Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.
Vivosim Labs Highlights FDA Rule Supporting Non‑Animal Drug Testing. Vivosim Labs announced that the FDA has issued a direct final rule allowing non‑animal methods for safety testing of drugs and biologics. The guidance confirms that the company’s non‑animal testing platform can be used in regulatory submissions. This regulatory clarification could broaden the market for Vivosim’s products and reduce the need for animal testing in drug development.